BIO-key Regains Nasdaq Compliance; Trading to Resume July 8th
BKYI sits 33% above its 52-week low of $3.1 on light trading volume (0.3× avg).
Summary
BIO-key International announced it has regained compliance with Nasdaq listing rules, and its common stock will recommence trading on the Nasdaq Capital Market on July 8, 2026.
Key Events · Corporate Governance and Compliance · BKYI
-
Nasdaq Reinstatement
BIO-key International, Inc. announced that its common stock will recommence trading on the Nasdaq Capital Market effective with the market's opening on Wednesday, July 8, 2026.
-
Compliance Achieved
The company regained compliance with Nasdaq's continued listing standards, including minimum bid price and SEC filing requirements, following a hearing with a Nasdaq Hearings Panel on June 16th.
-
Panel Monitor Period
BIO-key will be subject to a Discretionary Panel Monitor by Nasdaq for a period of one year, until July 6, 2027.
-
CEO Optimism
CEO Michael DePasquale expressed gratitude to Nasdaq and highlighted the company's growing recurring revenue, solid financial position, and expectation for significantly improved results this year.
Analysis · BKYI · Technology
This is a critical positive development for BIO-key, reversing the previous Nasdaq delisting and move to OTC Markets. Regaining a listing on a major exchange like Nasdaq is crucial for investor confidence, liquidity, and the company's ability to raise capital. It directly addresses a significant risk factor and a 'going concern' warning highlighted in recent filings, signaling a step back from financial distress and potentially opening the door for broader institutional investment.
At the time of this filing, BKYI was trading at $4.11 on OTC in the Technology sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $3.10 to $197.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.